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Common among several autoimmune diseases is a prominent interferon (IFN) signature caused 
by aberrant IFN-α production from plasmacytoid dendritic cells (pDC). This uncontrolled 
response occurs when pDCs are activated through endosomal toll-like receptors (TLR). Within 
the endosomal compartment, TLR 7/8 and 9 are stimulated through nuclear immune complexes. 
The objective of this work was to determine the eicosanoids associated with IFN-α production 
upon TLR stimulation of murine bone marrow derived dendritic cells. 
Female C57BL/6Ncrl mouse bone marrow was cultured in FLT3-ligand (FMS-like 
tyrosine kinase 3) for 8 days to generate dendritic cell subsets. On day 8, TLR ligands were 
added. Supernatant was analyzed for eicosanoids by liquid chromatography- mass spectrometry 
and cell pellets were analyzed for phospholipid fatty acid content by gas chromatography- mass 
spectrometry and IFN-α by ELISA. 
Murine pDCs stimulated with TLR 7 ligand Poly U (GU-rich ssRNA40), TLR 8 ligand 
R848 (resiquimod), and TLR 3 ligand Poly I:C (polyinosinic-polycytidylic acid) produced no 
observable IFN-α production. Upon stimulation with TLR 9 ligand ODN1585 CpG, IFN-α was 
significantly increased as compared to unstimulated no target samples. Targeted lipidomics 
analysis of eicosanoids showed that in cultures stimulated with TLR9 ligand, pro-inflammatory 
eicosanoid production of arachidonic acid mediators derived via cyclooxygenase, such as 
prostaglandin A2, B2, D2, and E2 and thromboxane B4, were increased while decreases were seen 
in lipoxygenase derived mediators. Phospholipid fatty acid analysis revealed low levels of α-
linoleic acid, dihomo-γ-linolenic acid, and arachidonic acid and high levels of EPA, DPA, and 
2 | P a g e  
 
DHA within the phospholipid membranes. Understanding the role of fatty acids associated with 
IFN-α production in pDCs may provide therapeutic and mechanistic targets for autoimmune 
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Literature Review 
Autoimmune diseases (AD) affect 23.5 million individuals in the U.S. (NIH, 2006) and 
are one of the top 10 leading causes of mortality in women under 65 years (Walsh & Rau, 2000). 
The chronic and life-threatening nature of many autoimmune diseases are debilitating and 
disabling, increasing financial and economic burdens on individual constituents (Tobias, 2010). 
While the exact trigger to autoimmune disease development is unknown, an individual’s 
exposome, or lifetime exposures, is a key factor in the development of autoimmune diseases, 
such as lupus. 
Affecting more than 5 million people worldwide and being one of the most commonly 
diagnosed autoimmune diseases annually, Lupus is a prevalent and problematic worldwide 
disease. Approximately 16,000 new cases are diagnosed each year (Danchenko et al., 2006).  In 
the United States, Lupus is more prevalent among African Americans and Asians as compared 
Caucasians (Danchenko et al., 2006; Cervera et al., 2009; Vasudevanand et al., 2010; Osio-
Salido & Manapat-Reys, 2010; Jakes et al., 2012). Lupus affects females more than males at a 
9:1 ratio, indicating possible female hormone involvement in the pathogenesis of the disease 
(Elkton and Stone., 2011).  Factors contributing to the development of Lupus include a 
combination of genetics, hormones, environment, and immunoregulation. Individuals diagnosed 
with lupus experience many life-altering and debilitating symptoms. These clinical symptoms 
encompass pain, extreme fatigue, cognitive issues, hair loss, and other major physical 
impairments. While Lupus presents with a relatively low mortality rate, if left untreated it could 
become fatal (Klarquist et al., 2016). 
Lupus manifests itself with a loss of self-tolerance to nuclear autoantigens and 
uncontrolled autoantibody and immune complex formation. This occurs with a lack of clearance 
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of dead and dying cells (Berkel et al, 1997; Shoshan et al, 2001) in conjunction with abnormal 
apoptosis (Herrmann et al, 1998; Lorenz and Anders, 2015). When these cells become apoptotic, 
they release their nuclear material into the surrounding environment, promoting the formation of 
immune complexes that induce the loss of self-tolerance and production of inflammatory 
cytokines. Abnormal autoantibody production due to loss of self-tolerance leads to aberrant 
production of genes encoding inflammatory agents, specifically type 1 interferon (IFN) 
production by plasmacytoid dendritic cells (pDCs), causing systemic inflammation, tissue, and 
organ damage (Lorenz et al., 2016). Serum and tissue samples of lupus patients have shown 
significant increases in apoptotic cells (Herrmann et al, 1998) and increased levels of type 1 
interferons (Kwok, et al., 2008), which can be correlated to active disease (Elkton and Stone, 
2011). Dendritic cells are important mediators in the immunological response as they are the 
cellular bridge between innate immunity and adaptive immunity (Gallo and Gallucci, 2013). 
Under homeostatic conditions, the main functions of dendritic cells are to clear necrotic and 
dying cells through efferocytosis, to present processed antigens to naïve T lymphocytes to induce 
regulatory T lymphocyte development (Jongbloed et al., 2010), and inhibition of autoreactive T 
lymphocyte development to maintain immunological self-tolerance (Goubier et al., 2008). 
Dendritic cell subsets vary in their cell surface markers, production of cytokines, and their ability 
to initiate immune responses. (Gallo and Gallucci, 2013). 
Plasmacytoid dendritic cells are a specialized subset of CD11c+ dendritic cells that are 
relatively long living (Shortman and Naik, 2006). While the exact cause of lupus is unknown, 
previous research shows that pDCs are involved in both the formation and progression of lupus 
(Yeste et al, 2012).  Plasmacytoid dendritic cells become activated when autoantigens bind to the 
FCγRIIa receptor on the surface of the cell, allowing the internalization of the autoantibody 
7 | P a g e  
 
complex into an endosomal compartment (Bave et al, 2003). Once inside the endosomal 
compartment, toll-like receptors (TLR) 3, 7/8 and 9 become activated. Toll-like receptors (TLRs) 
are a family of innate immune pattern recognition receptors (PRR) (Keating et al, 2011). These 
TLRs recognize foreign invading pathogenic material called pathogen-associated molecular 
patterns (PAMPs). TLR3 recognizes double-stranded viral RNA. TLR3 signals through the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) transcription 
factors and cytoplasmic toll-IL-1 domain (TIR domain) containing IFN-β (TRIF) to produce 
IFN-β in response to the viral pathogen (Siednieko et al., 2010; Okahira et al., 2005). Toll-like 
receptors 7/8 and 9 are nearly identical in signaling to produce pro-inflammatory cytokines, 
however they differ in their recognition of PAMPs. TLRs 7/8 recognizes single-stranded RNA 
and elicits and antiviral response upon stimulation, while TLR9 recognizes ssDNA, and upon 
recognition initiates an antibacterial immune response.  This activation creates a cascade of 
signaling events facilitated by adaptor proteins MyD88/TRAF3/IRF7, leading to translocation to 
the nucleus and transcription of genes encoding the production of inflammatory cytokines and 
type 1 IFN (Yang et al., 2005; Bao and Liu, 2012; Lorenz, et al., 2016; Kawai et al., 2004; Lee et 
al., 2003). pDCs respond to intracellular pathogens by producing type-1 IFN. 
Type 1 IFN is clinically important in the pathogenesis of lupus (Hooks et al., 1979). 
Many different cell types are capable of producing IFN-β; however, hematopoietic pDCs are 
unique in their ability to produce 10-100 times more IFN-α than any other cell type (Elkton & 
Stone, 2011). In response to the activation of TLR 7/8 and 9 by nuclear material, aberrant 
production of type-1 IFN occurs. Once pDCs begin secreting type-1 IFN into the surrounding 
environment, the exogenous type-1 IFN stimulates further production in an autocrine and 
paracrine fashion by binding to heterodimeric transmembrane INFAR 1/2 on the surface of the 
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pDC (Wu et al., 2016). Signaling through this pathway involves members of the JAK-STAT 
pathway to induce the expression of numerous modulatory IFN response genes (ISGs) (Crow et 
al., 2014; Wu et al., 2016). Aberrant IFN-α production leads to both the over production of other 
inflammatory cytokines and tissue damage (Gkirtzimanaki et al, 2018). Intervening in the self-
perpetuating production of type-1 IFN provides a pleiotropic target for the reduction of lupus 
development and disease severity as well as the reduction of other acute and chronic systemic 
inflammatory diseases that are otherwise difficult to treat (Ah Kioon et al, 2018; Ou Jin et al, 
2008). Therefore, much interest has been shown in inhibiting type-1 IFN production in pDCs 
(Zhuang et al., 2015; Lee et al., 2003; Mathian et al., 2015). Current immunotherapy techniques 
may be just as harmful as helpful and over time, treatments become less effective and many 
patients may look to more alternative methods to conventional pharmaceuticals in facilitating 
treatment of disease progression (Pestka et al., 2014). 
Treatment options differ from individual to individual based on severity and organ 
involvement of the disease. Currently, treatment options for lupus are designed towards 
controlling the damaging inflammatory process of the disease. Treatment options for lupus 
include immunosuppressive drugs such as corticosteroids, NSAIDS (non-steroidal anti-
inflammatory drugs), and hydroxychloroquine (Urowitz et al., 1976). Although useful in the 
suppression and treatment of symptoms, these treatment options have many adverse side effects 
that include secondary infections and organ damage. Safety concerns associated with many of 
these potent immunomodulatory treatments outweigh any significant clinical benefit (Yildrim-
Toruner and Diamond., 2011). Therefore, treatment of lupus presents itself as an important area 
of research to scientists of many different disciplines.  
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Polyunsaturated fatty acids (PUFAs) are fats that contain more than one carbon-carbon 
double bond in the backbone of their aliphatic chain. PUFAs are important biological compounds 
that are structurally diverse with varying chain lengths and degrees of unsaturation (Holuab & 
Kuksis, 1978). The varying amount of unsaturation plays a crucial role in membrane functions 
such as membrane protein function (Spector & Yorek, 1985).  PUFAs can then be classified as 
ω-3 or ω-6 based on the position of the double bond to the first carbon of the methyl group in the 
aliphatic chain. Dietary fats, such as PUFAs, have a strong influence on the immunological state 
and function of the immune system. Dietary fish oil (rich in ω-3 fatty acids) reduces and/or 
ameliorates the immunological effects of system wide inflammation in autoimmune disease by 
acting on numerous aspects of the uncontrolled immune response (Bates et al., 2016). Although 
humans and mammals require essential PUFAs to maintain cellular homeostasis and membrane 
structure and integrity, they are unable to synthesize them in vivo (Kong et al., 2010). Therefore, 
it is necessary to have a diet balanced in PUFAs. 
The addition of dietary anti-inflammatory ω-3 fatty acids (such as DHA or EPA) 
pleiotropically modulates eicosanoid production in different ways. Dietary ω-3 fatty acids can 
modulate eicosanoid production from arachidonic acid by increasing the ratio of ω-3: ω-6 
phospholipid fatty acids, competitively displacing arachidonic acid as a substrate for eicosanoid 
production. Those metabolites produced from the enzymatic oxidation of DHA/EPA produce 
pro-resolving mediators, such as resolvins, protectins, maresins, and lipoxins (Shaikh et al., 
2011; Calder 2016; Rajnavolgyi et al., 2014; Nastasi et al., 2015; Pestka, 2010; Carlsson et al., 
2015; Kong, 2011).   
Previous studies using NZBWF1 murine models have been primarily focused on pro-
inflammatory effects of omega-6 fatty acids (linoleic acid) and anti-inflammatory effects of 
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omega-3 fatty acids (docosahexaenoic acid) on T lymphocytes (Nataraj et al, 2001), B 
lymphocytes (Rockett et al, 2010), and monocytes (Bingzhong et al, 2012) and the ability of 
omega-3 fatty acids to ameliorate SLE symptoms and progression in murine models (Pestka et 
al., 2014; Kong, 2011). Results of these studies show that cellular treatment of ω-3 fatty acids 
causes both a direct and indirect decrease in aberrant B and T lymphocyte activation and 
proliferation, cellular cytotoxicity, cellular chemotaxis, upregulated MHC II expression, and 
antigen presentation (Pestka et al., 2014; Kong et al., 2010; Kong, 2011). Pestka et al (2014) and 
Bates et al (2016) have shown strong evidence that nutritional supplementation dietary ω-3 fatty 
acids ameliorate lupus symptoms and disease progression in murine models.  However, there is a 
lack of understanding of the effects that ω-3 fatty acids have on pDCs, especially on pro-
inflammatory IFN-α production of pDCs. Although studies have shown that the addition of anti-
inflammatory ω-3 PUFAs alters the phospholipid membrane structure and fluidity of 
lymphocytes, research is lacking as to whether ω-3 fatty acids affect phospholipid membrane 
fluidity, intracellular signaling, and anti-inflammatory eicosanoid production in pDCs. The focus 
of our laboratory is the investigation of both intrinsic and extrinsic effects that ω-3 fatty acid 
supplementation has on murine bone marrow-derived pDC phenotype and function, fatty acid 











C57BL/6NCrl female mice were purchased from Charles River Laboratories at 5-6 weeks of age. 
Mice were housed four per cage in a clean animal facility at the University of Michigan-Flint. 
They were allowed free access to both 18% protein Teklad irradiated chow diet (Envigo 2918) 
feed and water. The animal facility was kept at a constant temperature and humidity and the mice 
were subjected to 12-hour light/dark cycles.  All animal protocols were reviewed and approved 
by the Institutional Animal Care and Use Committee at the University of Michigan according to 
federal guidelines. The mice were sacrificed via CO2 asphyxiation with secondary cardiac 
puncture and heart removal. The tibia, fibula, and femur were collected for bone marrow 
aspiration. Bone marrow cells were flushed with RPMI. Cells were lysed with ACK lysis buffer 
(155nM ammonium chloride, 10mM potassium bicarbonate, 0.1mM EDTA) and plated at a 
density of 1.0*106 cells/mL in 12 well plates with complete RPMI-1640 [10% fetal bovine serum 
(Hyclone), 1x Penicillin/Streptomycin, 1x non-essential amino acids, 1x sodium pyruvate, 50μM 
beta mercaptoethanol] supplemented with 200ng/mL recombinant murine FLT3-L (PreproTech, 
Rocky Hill, NJ) and incubated at 37℃, 5% CO2 for 9 days. 
 
TLR Agonist Stimulation 
On day 8 of the culture, the cells were stimulated with TLR8 agonist Poly(U) (InvivoGen) at 
5μg/mL, TLR3 agonist Polyinosinic-polycytidylic acid (Poly I:C, InvivoGen, San Diego, CA) at 
1μg/mL, TLR9 agonist ODN 1585 CpG oligonucleotide (InvivoGen, San Diego, CA) at 1μM, 
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and TLR7/8 agonist Resiquimod (R848, InvivoGen, San Diego, CA) at 1μg/mL and incubated at 
37℃, 5% CO2 for 24 hours. 
 
Immunofluorescent Intracellular Staining and Flow Cytometry 
Surface immunophenotyping of cell culture with fluorochrome-conjugated monoclonal 
antibodies and intracellular staining for IFNα protein were performed to identify cell-specific 
intracellular IFNα production. For intracellular staining, the cells were stimulated with TLR 
ligands as described above and incubated for 16 hours with the addition of 1μl/mL of GolgiPlug 
(Brefeldin A; BD Biosciences, San Jose, CA) for the final 8 hours of the 24-hour stimulation. 
Cells were harvested by vigorous pipetting and washing with Ca++/Mg++ free fluorescence 
activated cell sorting (FACS) buffer. Cells were blocked with anti-CD16/anti-CD32 (Fc Block, 
BD Biosciences, San Jose, CA) for 10 minutes on ice. Subsequently, cells were surface labeled 
with anti-IFNαR-PE (Leinco Technologies, Fenton, MO), anti-CD11c-APC (BD Biosciences, 
San Jose, CA), anti-B220-PerCp-eFluor710 (BioLegend, San Diego, CA). Cells were washed 
with FACS buffer, fixed with paraformaldehyde, and permeabilized with saponin according to 
manufacturer instructions (BD Biosciences, San Jose, CA). Fixed and permeabilized cells were 
stained intracellularly with fluorochrome-conjugated anti-IFNα-FITC (PBL assay science, 
Piscataway, NJ). The samples were acquired via flow cytometric analysis using a BD 
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Quantification of IFNα 
To confirm and quantify the presence of IFN-α, cell cultures (without GolgiPlug) were 
centrifuged at 320xg for 10 minutes at 4℃ to separate cells from the supernatant. The 
supernatant was used to perform an ELISA (PBL Assay Science, Piscataway, NJ) to detect and 
quantify IFN-α production. In following the manufacturer’s protocol, the standard and 
appropriate sample dilutions were made, and the diluted detection antibody solution was added. 
The plate incubated at 25℃ while on a plate shaker at 200RPM for 2 hours and was stored at 
4℃ for 20-24 hours. The plate was washed four times with diluted wash solution and HRP was 
added. The plate was incubated on a plate shaker at 25℃ for 2 hours. After incubation, TMB 
substrate (PBL Assay Science, Piscataway, NJ) was added to each well, followed by 15-minute 
incubation and the addition of stop solution. The absorbance was read at 450nm on a microplate 
reader and a standard curve was generated. 
 
Lipidomics Analysis 
Pellets of cells stimulated with TLR agonists were collected and stored at -80C until submission 
to the University of Michigan Regional Comprehensive Metabolomics Resource Core (Ann 
Arbor, MI) for analysis of phospholipid fatty acids (palmitic acid, palmitoleic acid, stearic acid, 
oleic acid, and arachidonic acid). The lipids were extracted from the sample matrix, 
transesterification phospholipids to methyl esters occurred, and then analyzed via GCMS. 
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Metabolomics Analysis 
Supernatant samples of cells stimulated with TLR agonists were collected and sent to the 
University of Michigan Regional Comprehensive Metabolomics Resource Core (Ann Arbor, MI) 
eicosanoid analysis. Using solid phase extraction, eicosanoids are extracted, concentrated, dried 
and re-suspended for separation by LCMS/RPLC. 
 
Data Analysis 
Duplicate lipidomic samples were averaged and mean no target values were subtracted. A heat 
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Results 
From two C57BL/6NCrl female mice, 3.88*107 hematopoietic bone marrow cells were obtained 
and plated in 12 well culture plates at a density of 1.0*106 cells/mL and supplemented with 
200ng/mL of recombinant murine FLT3-L for 9 days to induce dendritic cell expansion of 
myeloid and lymphoid dendritic cell populations. The cells were blocked via Fc block and 
surface labeled with anti-CD11c-APC, and anti-IFNαR-PE (data not shown). Phenotypic 
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Figure 1- Phenotypic Analysis of FL3-L Induced Myeloid and Lymphoid Dendritic Cell 
Populations. 
a)        b)     c)  
A sequential gating strategy used to identify FLT3-L induced myeloid and lymphoid dendritic 
cell populations from culture. a) Forward scatter (FSC) and side scatter (SSC) of cell populations 
to gate out lymphocytic cell population. b-c) Gating strategy to identify cDCs and pDCs 
expressing specific cell markers. In figure b, cells that are CD11c+/B220- are cDC cell 
population.  38.6% +/- 0.867% [Standard error of the mean (SEM)] of cells in figure b are 
CD11c DIM/B220+ are pDC cell population. Figure c is the remaining gating strategy to identify 
13.6%  +/- 2.27% CD8-like cDCs and 2.87%  +/- 0.48% CD11b-like cCDs. The CD8-like cDCs 
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On day 8, the cells were stimulated with TLR 3 agonist Poly(I:C) or TLR 9 agonist ODN 1585 
CpG for 24 hours. To confirm IFN-α production, intracellular staining was performed and 
analyzed via flow cytometry (data not shown). The supernatant of the cell cultures was collected 
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Figure 2- Quantification of IFN-α Production across TLR Stimulations 
 
 
An ELISA was performed using the supernatant of the cell cultures of cells stimulated through 
TLRs to detect and quantify the inducible IFN-α production. In the cells lacking TLR stimulation 
(No target) IFN-α was not detectable. Cells were further stimulated via TLR 9 agonist CpG, TLR 
3 agonist pIC, and TLR 7/8 agonist R848. From the stimulation, quantifiable amounts at 2963 
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Cells were pelleted and sent to the University of Michigan Regional Comprehensive 
Metabolomics Resource Core for phospholipid fatty acid analysis. Supernatant of the stimulated 
cell cultures was collected and also sent to the University of Michigan Regional Comprehensive 
Metabolomics Resource Core for analysis of lipid mediators/eicosanoids that are involved in 















20 | P a g e  
 
Table 1- Phospholipid Fatty Acid Lipidomic Changes due to TLR Stimulation 
 
Results of lipidomics analysis of 25 tested phospholipid fatty acid concentration (n mol) per 
stimulation. Cells were cultured and stimulated in duplicates. NT-A and NT-B consist of bone 
marrow-derived dendritic cell pellets of cells that were cultured in RPMI-1640 and were lacking 
stimulation through TLR agonists. Duplicate stimulations of pIC and CpG consist of cell pellets 
of cells cultured in RPMI-1640 and stimulated with TLR3 (poly(I:C)) or TLR9 (CpG) agonists 
for 24 hours. 14:0-myristic acid, 14:1- Myristoleic acid, 16:0- Hexadecenoic acid, 16:1- 
Palmitoleic acid, 18:0- Octadecanoic acid, 18:1 (n-7)- Vaccenic acid, 18:1 (n-9)-oleic acid, 18:2-
linoleic acid, 18:3 (n-3)-α-linolenic acid, 18:3 (n-6)-γ -linoleic acid, 20:0-Arachididic acid, 20:1- 
Eicosanoic acid, 20:2- Eicosadienoic acid, 20:3- dihomo-γ-linolenic acid, 20:4- Arachidonic 
acid, 20:5- Eicosapentaenoic acid (EPA), 21:0- Heineicosanoic acid, 22:0- Eicosanoic acid, 22:1- 
Eruic acid, 22:2- Docosadienoic acid, 22:4- Docosatetraenoic acid, 22:5- Docosapentaenoic acid, 
22:6- Docosahexaenoic acid (DHA), 24:0-Tetracosanoic acid, 24:1-Nervonic acid. An increase is 
seen in total phospholipid fatty acid concentrations in CpG-A. 
 
PL-FA Profile NT-A (%) NT-A NT-B (%) NT-B pIC-A (%) pIC-A pIC-B (%) pIC-B CpG-A (%) CpG-A CpG-B (%) CpG-B
Name Amt (n mol) percent (%) Amt (n mol) percent (%) Amt (n mol) percent (%) Amt (n mol) percent (%) Amt (n mol) percent (%) Amt (n mol) percent (%)
14:0 0.03 0.47 0.04 0.40 0.01 0.18 0.02 0.19 0.06 0.25 0.02 0.20
14:1 (n-5) 0.41 5.61 0.40 4.28 0.48 6.19 0.36 2.86 0.47 2.10 0.43 3.45
16:0 1.39 19.21 0.89 9.63 0.75 9.65 1.66 13.19 1.78 8.04 1.19 9.46
16:1 (n-7)c 0.02 0.29 0.06 0.62 0.05 0.66 0.09 0.73 0.04 0.17 0.13 1.02
18:00 3.03 41.78 3.94 42.73 3.92 50.73 5.75 45.62 11.53 52.10 4.88 38.76
18:1(n-7) 0.17 2.39 0.24 2.65 0.27 3.49 0.34 2.67 0.51 2.31 0.41 3.27
18:1(n-9) 0.48 6.59 0.50 5.45 0.55 7.06 0.68 5.38 1.58 7.14 0.70 5.58
18:2 (n-6) 0.14 1.90 0.15 1.57 0.17 2.21 0.19 1.53 0.33 1.48 0.25 1.96
18:3 (n-3) 0.02 0.23 0.07 0.75 0.02 0.30 0.00 0.00 0.03 0.14 0.02 0.17
18:3 (n-6) 0.09 1.20 0.10 1.10 0.07 0.89 0.03 0.24 0.20 0.91 0.08 0.64
20:0 0.08 1.14 0.00 0.00 0.00 0.00 0.05 0.40 0.24 1.09 0.00 0.00
20:1 0.00 0.00 0.00 0.00 0.03 0.44 0.00 0.00 0.05 0.24 0.00 0.00
20:2 0.00 0.00 0.00 0.00 0.05 0.65 0.09 0.71 0.11 0.48 0.06 0.44
20:3 (n-6) 0.03 0.48 0.00 0.00 0.07 0.95 0.09 0.68 0.00 0.00 0.15 1.18
20:4 (n-6) 0.08 1.04 1.13 12.27 0.03 0.34 1.52 12.09 2.15 9.72 2.06 16.36
20:5 (n-3) 0.06 0.83 0.09 0.98 0.13 1.64 0.10 0.83 0.24 1.09 0.05 0.43
21:0 0.07 1.03 0.11 1.21 0.06 0.77 0.07 0.54 0.29 1.30 0.08 0.63
22:0 0.20 2.78 0.19 2.07 0.07 0.93 0.36 2.83 0.14 0.65 0.10 0.83
22:1 0.25 3.47 0.26 2.76 0.24 3.07 0.05 0.36 0.34 1.56 0.31 2.48
22:2 (n-6) 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.33 0.00 0.00 0.08 0.65
22:4 (n-6) 0.16 2.16 0.28 3.01 0.24 3.17 0.37 2.91 0.67 3.02 0.47 3.72
22:5 (n-3) 0.03 0.35 0.08 0.82 0.11 1.44 0.17 1.35 0.19 0.87 0.25 1.96
22:6 (n-3) 0.02 0.30 0.11 1.14 0.15 1.96 0.15 1.21 0.25 1.13 0.27 2.15
24:0 0.26 3.56 0.12 1.29 0.00 0.00 0.19 1.48 0.26 1.16 0.26 2.08
24:1 0.23 3.20 0.48 5.25 0.25 3.29 0.24 1.87 0.68 3.06 0.32 2.57
Sum (n mol) 7.26 100.00 9.23 100.00 7.73 100.00 12.60 100.00 22.13 100.00 12.59 100.00
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Table 2- Average Concentration and Average Relative Percent of Phospholipid Fatty Acids due 
to TLR Stimulation 
 
Fatty acid concentrations (n mol) among duplicate cultures were averaged for each individual 
fatty acid present in the lipidomics analysis. The average total among duplicate cultures was also 
calculated. From the average fatty acid concentrations for each individual fatty acid and the 
average total, the average percent of each fatty acid was calculated by taking the calculated 
average fatty acid concentration, dividing it by the average total concentration, and multiplying 
that value by 100 to get a percent of each fatty acid as a part of the total. 14:0-myristic acid, 
14:1- Myristoleic acid, 16:0- Hexadecenoic acid, 16:1- Palmitoleic acid, 18:0- Octadecanoic 
acid, 18:1 (n-7)- Vaccenic acid, 18:1 (n-9)-oleic acid, 18:2-linoleic acid, 18:3 (n-3)-α-linolenic 
acid, 18:3 (n-6)-γ -linoleic acid, 20:0-Arachididic acid, 20:1- Eicosanoic acid, 20:2- 
Eicosadienoic acid, 20:3- dihomo-γ-linolenic acid, 20:4- Arachidonic acid, 20:5- 
Eicosapentaenoic acid (EPA), 21:0- Heineicosanoic acid, 22:0- Eicosanoic acid, 22:1- Eruic 
acid, 22:2- Docosadienoic acid, 22:4- Docosatetraenoic acid, 22:5- Docosapentaenoic acid, 22:6- 
PL-FA Profile Average NT (%) Ave Percent NT Average pIC (%) Ave Percent pIC Average CpG (%) Ave Percent CpG
Name Amt (n mol) percent (%) Amt (n mol) percent (%) Amt (n mol) percent (%)
14:0 0.04 0.42 0.02 0.15 0.04 0.23
14:1 (n-5) 0.41 4.87 0.42 4.13 0.45 2.59
16:0 1.14 13.70 1.21 11.85 1.49 8.56
16:1 (n-7)c 0.04 0.48 0.07 0.69 0.09 0.26
18:00 3.49 41.89 4.84 47.57 8.21 47.28
18:1(n-7) 0.21 2.46 0.31 3.00 0.46 2.65
18:1(n-9) 0.49 5.89 0.62 6.05 1.14 6.57
18:2 (n-6) 0.15 1.74 0.18 1.77 0.29 1.67
18:3 (n-3) 0.05 0.54 0.01 0.10 0.03 0.14
18:3 (n-6) 0.10 1.14 0.05 0.49 0.14 0.81
20:0 0.04 0.48 0.03 0.25 0.12 0.69
20:1 0.00 0.00 0.02 0.15 0.03 0.14
20:2 0.00 0.00 0.07 0.69 0.09 0.49
20:3 (n-6) 0.02 0.18 0.08 0.79 0.08 0.43
20:4 (n-6) 0.61 7.27 0.78 7.62 2.11 12.13
20:5 (n-3) 0.15 1.80 0.12 1.13 0.15 0.84
21:0 0.09 1.08 0.07 0.64 0.19 1.07
22:0 0.20 2.34 0.22 2.12 0.12 0.69
22:1 0.26 3.06 0.15 1.43 0.33 1.87
22:2 (n-6) 0.00 0.00 0.02 0.20 0.04 0.23
22:4 (n-6) 0.22 2.64 0.31 3.00 0.57 3.28
22:5 (n-3) 0.06 0.66 0.14 1.38 0.22 1.27
22:6 (n-3) 0.07 0.78 0.15 1.48 0.26 1.50
24:0 0.19 2.28 0.10 0.93 0.26 1.50
24:1 0.36 4.27 0.25 2.41 0.50 2.88
Sum (n mol) 8.32 100.00 10.17 100.00 17.36 100.00
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Docosahexaenoic acid (DHA), 24:0-Tetracosanoic acid, 24:1-Nervonic acid. Average total fatty 
acid concentrations increase along with 20:4, 22:3, 22:6 due to stimulation through TLR9 agonist 
CpG. Conversely, decreases were seen in the average percent fatty acids of 16:1, 18:3(n-3), 
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Table 3- Heat Map Representing Relative Percent Change in Phospholipid Fatty Acid Across 
TLR Stimulations 
PL-FA Profile pIC-A pIC-B CpG-A CpG-B 
Name % Change % Change % Change % Change 
14:0 69.34 62.26 36.32 62.26 
14:1 (n-5) 26.43 41.78 56.84 30.58 
16:0 29.85 4.75 41.85 31.66 
16:1 (n-7) c 31.96 46.39 62.89 112.37 
18:0 19.97 7.95 41.28 78.33 
18:1(n-7) 40.87 8.61 7.48 107.56 
18:1(n-9) 19.81 9.14 20.14 53.39 
18:2 (n-6) 25.07 14.72 15.29 13.13 
18:3 (n-3) 52.81 100.00 76.19 70.67 
18:3 (n-6) 20.01 79.17 21.89 45.31 
20:0 100 19.59 122.68 100 
20:1 39.00 0.00 23.00 0.00 
20:2 64.00 50.00 71.00 48.00 
20:3 (n-6) 400 290.1 100 553.85 
20:4 (n-6) 94.82 64.35 90.73 122.95 
20:5 (n-3) 84.62 13.19 18.68 57.14 
21:0 28.57 48.72 19.96 42.31 
22:0 61.95 20.93 73.36 66.60 
22:1 204.59 63.30 42.84 125.69 
22:2 (n-6) 0.00 32.00 0.00 64.00 
22:4 (n-6) 161.92 9.82 13.19 39.81 
22:5 (n-3) 112.89 100.9 28.94 198.35 
22:6 (n-3) 14.619 51.02 42.132 171.574 
24:0 100 91.75 88.72 88.72 
24:1 94.19 94.43 84.2 92.57 
 
 
A heat map was generated from the lipidomics data comparing relative percent change in 
phospholipid fatty acids across differing TLR stimulations. NT samples are duplicate cell 
cultures of FLT3-L induced bone marrow-derived dendritic cells cultured in RPM-1640 lacking 
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TLR agonistic stimulation. Poly(I:C) and CpG duplicate cultures are cultured in RPMI-1640 
stimulated with TLR agonists. Decreasing percentages from the control value are depicted in 
varying shades of red while increasing percentages are depicted in varying shades of green. 
Those values that remained unchanged or undetected are shown in black. To calculate the 
percent change, the average phospholipid fatty acid concentration for each fatty acid was 
determined for NT. The average NT total concentration was also calculated. From these 
calculations, the total percent of each NT was calculated. The percent of each individual fatty 
acid was calculated for both poly(I:C) stimulations and for both CpG stimulations. Finally, to 
determine the relative change in percent of each phospholipid fatty acid, the percent of the whole 
fatty acid of each stimulation was subtracted from the total percent of each NT fatty acid, divided 
by the total percent of each NT fatty acid, and multiplied by 100% to yield the relative percent 
change of each phospholipid fatty acid from the NT. 
Lipidomics analysis shows a 100% decrease in dihomo-γ-linolenic acid (20:3) in CpG-A 
stimulation and a marked 554% increase in CpG-B stimulation. A 91% decrease in arachidonic 
acid (20:4) was noted in CpG-A stimulation, while a 123% increase occurred in CpG-B. 
Analysis shows a 19% increase in EPA (20:5) with CpG-A stimulation while there was a 57% 
decrease in CpG-B. In CpG-A, DHA (22:6) increased 42%, while in CpG-B there was a dramatic 
172% increase. Palmitoleic acid (16:1) decreased 63% upon stimulation with CpG-A, however 
increased 112% in CpG-B. While DPA (22:5) increased throughout all stimulations, it was not as 
increased in CpG-A. 
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Table 4- Omega-3: Omega-6 Ratio of Average Fatty Acid Concentrations Across Stimulations 
Fatty Acid NT pIC CpG 
18:3 n-3 (ALA) 0.05 0.10 0.03 
20:5 n-3 (EPA) 0.15 1.13 0.15 
22:5 n-3 (DPA) 0.06 1.38 0.22 
22:6 n-3 (DHA) 0.07 1.48 0.26 
TOTAL n-3 0.33 4.09 0.66 
    
18:2 n-6 (LA) 0.15 0.18 1.67 
20:3 n-6 (DGLA) 0.02 0.08 0.08 
20:4 n-6 (AA) 0.61 0.78 2.11 
22:4 n-6  0.22 0.31 0.57 
TOTAL n-6 1.00 1.35 4.43 
OMEGA-6 
/OMEGA-3   
 
3.03 0.33 6.71 
 
The ω-6: ω-3 ratio was calculated from the average concentrations (n mol) of each of the listed 
unesterified ω-6 and ω-3 fatty acids. Average concentrations were summed for ω-3 fatty acids 
and ω-6 fatty acids and then the ω-6 average total concentration (n mol) was divided by the 
average total ω-3 (n mol) across each stimulation and the NT. NT samples are duplicate cell 
cultures of FLT3-L induced bone marrow-derived dendritic cells cultured in RPM-1640 lacking 
TLR agonistic stimulation. Poly(I:C) and CpG duplicate cultures are cultured in RPMI-1640 
stimulated with TLR agonists. ω-3 and ω-6 unesterified fatty acids used in calculating ω-6: ω-3 
ratio include: 18:3 n-3: α-linolenic acid, 20:5 n-3: eicosapentaenoic acid (EPA), 22:5 n-3: 
docosapentaenoic acid (DPA), 22:6 n-3: docosahexaenoic acid (DHA), 18:2 n-6: linoleic acid, 
20:3 n-6: dihomo-γ-linolenic acid, 20:4 n-6: arachidonic acid, 22:4 n-6: docosatetraenoic acid. In 
the culture cells lacking TLR stimulation (NT), the ω-6: ω-3 ratio value is 3.03. Upon 
stimulation with Poly(I:C), the ω-6: ω-3 ratio is 0.33, indicating the omega-6:omega-3 ratio 
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shifted toward omega-3 PUFAs. Conversely, upon stimulation with TLR9 agonist CpG, the ω-6: 
ω-3 ratio was 6.71. This was greater than a two-fold increase as compared to NT cell unesterified 
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Table 5- Lipid Mediator Production due to Differing TLR Stimulation  
 
11-HETE- 11S-hydroxy-5Z,8Z,11E, 14Z-eicosatetraenoic acid; 12-oxoETE- 12-oxo-
5Z,8Z,10E,14Z-eicosatetraenoic acid; 5s-HETE-5-hydroxyeicosatetraenoic acid; 12s-HETE- 12-
hydroxyeicosatetraenoic acid, 13s-HODE- 13-hydroxyoctadecadienoic acid; 15s-HETE- 15-
hydroxyeicosatetraenoic acid; 20s-HETE- 20-hydroxyeicosatetraenoic acid; 5oxoETE- 5-oxo-
6E,8Z,11Z,14Z-eicosatetraenoic acid; 6kPSGF1a- 6-keto-prostaglandin F1 alpha; 8-HETE- 8-
hydroxyeicosatetraenoic acid; 9-HETE- 9-hydroxyeicosatetraenoic acid; 9s-HODE- 9-
hydroxyoctadecadienoic acid; LKTB4- leukotriene B4; PSG_D2- prostaglandin D2; PSG E2- 
prostaglandin E2; PSG F2a- prostaglandin F2 alpha; PSG_A2- prostaglandin A2; PSG B2- 
prostaglandin B2; RSV_D1- resolvin D1; RSV_D2- resolvin D2; RSV_E1-resolvin E1; TB B2- 
thromboxane B2. An increase in total eicosanoid concentration is seen in CpG-B. Concentration 
amounts shown in μM. Percentages shown are percent of each eicosanoid present based off of 
the total of each stimulation. Culture and stimulations were duplicated (A and B). No target (NT) 
samples are cells cultured in RPMI-1640 lacking stimulation with TLR agonists, whereas pIC 
Eicosanoids NT-A (%) NT-A NT-B (%) NT-B pIC-A (%) pIC-A pIC-B (%) pIC-B CpG-A (%) CpG-A CpG-B (%) CpG-B
Name Amount (μM) % Amount (μM) % Amount (μM) % Amount (μM) % Amount (μM) % Amount (μM) %
11_HETE 1.27 0.63 1.25 0.87 1.26 0.72 0.92 1.22 1.25 0.87 1.82 0.76
12oxoETE 11.95 5.89 2.95 2.07 14.67 8.41 3.75 4.99 0.20 0.14 0.21 0.09
12s HETE 1.03 0.51 0.74 0.52 1.30 0.74 1.00 1.33 0.79 0.55 1.19 0.49
13S-HODE 7.02 3.46 6.57 4.59 8.10 4.64 6.71 8.93 7.63 5.29 9.15 3.79
15s HETE 4.07 2.01 2.67 1.87 2.84 1.63 2.13 2.83 2.37 1.64 3.23 1.34
20S HETE 10.92 5.39 3.35 2.34 8.79 5.04 4.53 6.04 6.20 4.30 3.28 1.36
5oxoETE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
5s HETE 6.36 3.14 3.15 2.21 6.29 3.60 3.72 4.95 2.68 1.86 2.26 0.94
6k PSG F1a 1.82 0.90 2.67 1.87 2.47 1.42 1.95 2.60 2.02 1.40 2.16 0.90
8_HETE 2.06 1.02 1.46 1.02 1.05 0.60 0.31 0.41 0.72 0.50 3.07 1.27
9_HETE 0.11 0.05 0.00 0.00 2.09 1.20 0.00 0.00 0.80 0.55 1.29 0.53
9S-HODE 138.95 68.52 102.03 71.38 106.21 60.89 28.70 38.21 97.74 67.75 194.55 80.63
LKT B4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PSG_D2 1.40 0.69 1.15 0.81 1.78 1.02 1.59 2.12 1.50 1.04 1.58 0.65
PSG E2 2.37 1.17 2.12 1.48 3.01 1.73 2.70 3.59 2.99 2.07 2.53 1.05
PSG F2a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PSG_A2 1.73 0.84 1.61 1.13 3.10 1.78 2.56 3.41 3.12 2.17 1.20 0.50
PSG B2 1.82 0.90 1.76 1.23 1.84 1.05 1.87 2.49 2.05 1.42 1.93 0.80
RSV_D1 7.72 3.81 7.05 4.93 7.17 4.11 10.23 13.62 9.82 6.80 9.62 3.99
RSV_D2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
RSV_E1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
TB B2 2.16 1.07 2.40 1.68 2.46 1.41 2.45 3.26 2.39 1.66 2.22 0.92
Total 202.75 100.00 142.93 100.00 174.42 100.00 75.10 100.00 144.25 100.00 241.29 100.00
28 | P a g e  
 
and CpG samples are cells cultured in RPMI-1640 with TLR3 (pIC) and TLR9 (CpG) agonists. 
Culture supernatant was sent to Michigan Regional Comprehensive Metabolomics Core Facility 

















29 | P a g e  
 
Table 6- Average Concentration and Average Relative Percent of Eicosanoid Production due to 
Differing TLR Agonists 
 
Eicosanoid values for duplicate cultures were averaged. The total eicosanoids produced (μM) in 
duplicate cultures were also averaged. From these values, the average percent of each individual 
eicosanoid produced was calculate from the average total by taking the average total eicosanoid 
per stimulation, dividing that value by the average total for that stimulation, and multiplying that 
value by 100 to generate the average percentage of each eicosanoid as part of the total 
concentration of eicosanoid per stimulation. NT samples are cultures of murine FLT3-L induced 
bone marrow-derived dendritic cells cultured in RPMI-1640 without any TLR agonist. 
Conversely, pIC and CpG are cultures of FLT3-L induced bone marrow-derived dendritic cells 
cultured in RPMI-1640 for 9 days with a 24-stimulation with TLR3 (pIC) or TLR (TLR9) 
agonist. After the 24-hour stimulation, cell culture supernatant was sent to Michigan Regional 
Eicosanoids Ave NT  Ave (%)  NT Ave pIC  Ave (%)  pIC Ave CpG  Ave (%)  CpG
Name Amount (uM) Percent (%) Amount (μM) Percent (%) Amount (uM) Percent (%)
11_HETE 1.26 0.73 1.09 0.87 1.54 0.80
12oxoETE 7.45 4.31 9.21 7.38 0.20 0.11
12s HETE 0.89 0.51 1.15 0.92 0.99 0.51
13S-HODE 6.80 3.93 7.40 5.93 8.39 4.35
15s HETE 3.37 1.95 2.48 1.99 2.80 1.45
20S HETE 7.14 4.13 6.66 5.34 4.74 2.46
5oxoETE 0.00 0.00 0.00 0.00 0.00 0.00
5s HETE 4.76 2.75 5.00 4.01 2.47 1.28
6k PSG F1a 2.25 1.30 2.21 1.77 2.09 1.08
8_HETE 1.76 1.02 0.68 0.54 1.89 0.98
9_HETE 0.05 0.03 1.04 0.84 1.04 0.54
9S-HODE 120.49 69.71 67.45 54.07 146.14 75.81
LKT B4 0.00 0.00 0.00 0.00 0.00 0.00
PSG_D2 1.28 0.74 1.69 1.35 1.54 0.80
PSG E2 2.24 1.30 2.85 2.29 2.76 1.43
PSG F2a 0.00 0.00 0.00 0.00 0.00 0.00
PSG_A2 1.67 0.97 2.83 2.27 2.16 1.12
PSG B2 1.79 1.04 1.85 1.49 1.99 1.03
RSV_D1 7.39 4.27 8.70 6.97 9.72 5.04
RSV_D2 0.00 0.00 0.00 0.00 0.00 0.00
RSV_E1 0.00 0.00 0.00 0.00 0.00 0.00
TB B2 2.28 1.32 2.45 1.96 2.31 1.20
Total 172.84 100.00 124.76 100.00 192.77 100.00
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Comprehensive Metabolomics Core Facility for eicosanoid analysis.  11-HETE- 11S-hydroxy-
5Z,8Z,11E, 14Z-eicosatetraenoic acid; 12-oxoETE- 12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic 
acid; 5s-HETE-5-hydroxyeicosatetraenoic acid; 12s-HETE- 12-hydroxyeicosatetraenoic acid, 
13s-HODE- 13-hydroxyoctadecadienoic acid; 15s-HETE- 15-hydroxyeicosatetraenoic acid; 20s-
HETE- 20-hydroxyeicosatetraenoic acid; 5oxoETE- 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid; 
6kPSGF1a- 6-keto-prostaglandin F1 alpha; 8-HETE- 8-hydroxyeicosatetraenoic acid; 9-HETE- 
9-hydroxyeicosatetraenoic acid; 9s-HODE- 9-hydroxyoctadecadienoic acid; LKTB4- leukotriene 
B4; PSG_D2- prostaglandin D2; PSG E2- prostaglandin E2; PSG F2a- prostaglandin F2 alpha; 
PSG_A2- prostaglandin A2; PSG B2- prostaglandin B2; RSV_D1- resolvin D1; RSV_D2- 
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Table 7- Heat Map representing Relative Percent Change of Eicosanoids Across TLR 
Stimulations 
Column1 pIC-A pIC-B CpG-A CpG-B 
Eicosanoids % Change % Change % Change % Change 
11_HETE 1.10 19.51 67.58 150.55 
12oxoETE 95.08 15.75 96.75 97.91 
12s HETE 31.44 134.46 2.31 12.97 
13S-HODE 18.10 127.28 34.64 3.54 
15s HETE 16.41 45.13 15.89 31.80 
20S HETE 44.38 46.32 4.17 67.05 
5oxoETE 0.00 0.00 0.00 0.00 
5s HETE 30.86 79.94 32.39 65.83 
6k PSG F1a 8.46 100.00 61.54 30.78 
8_HETE 40.95 59.65 50.79 25.00 
9_HETE 3650.00 100.00 1618.75 1565.63 
9S-HODE 12.66 45.20 40.27 15.66 
LKT B4 0.00 0.00 0.00 0.00 
PSG_D2 38.02 186.87 40.73 12.04 
PSG E2 33.39 176.79 59.60 19.04 
PSG F2a 0.00 0.00 0.00 0.00 
PSG_A2 83.88 252.27 124.17 17.34 
PSG B2 1.25 140.16 36.93 22.85 
RSV_D1 3.82 218.75 59.14 125.18 
RSV_D2 0.00 0.00 0.00 0.00 
RSV_E1 0.00 0.00 0.00 0.00 
TB B2 6.90 147.16 28.85 30.25 
 
 
 Heat Map representing Relative Percent Change of Eicosanoids Across TLR Stimulations:  A 
heat map was generated from the data received from the Metabolomics Resource Core pertaining 
to eicosanoid and lipid mediator changes as a relative percent change of eicosanoids across 
stimulations as compared to the control. NT samples are duplicate cell cultures of FLT3-L 
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induced bone marrow-derived dendritic cells cultured in RPM-1640 lacking TLR agonistic 
stimulation. Poly(I:C) and CpG duplicate cultures are cultured in RPMI-1640 stimulated with 
TLR agonists. Decreasing values are depicted by varying shades of red while increasing values 
are depicted in differing shades of green. Those values remaining unchanged or undetected are 
shown in black. To calculate the percent change, the average eicosanoid concentration for each 
eicosanoid was determined for NT. The average NT total concentration was also calculated. 
From these calculations, the total percent of each NT was calculated. The percent of each 
individual eicosanoid was calculated for both poly(I:C) stimulations and for both CpG 
stimulations. Finally, to determine the relative change in percent of each eicosanoid, the percent 
of the whole eicosanoid of each stimulation was subtracted from the total percent of each NT 
eicosanoid, divided by the total percent of each NT eicosanoid, and multiplied by 100% to yield 
the relative percent change of each eicosanoid from the NT. 
 Due to stimulation with CpG, decreases were seen in 12-oxoETE, 5s-HETE and 
6kPSGF1a, while an increase due to CpG stimulation was seen in 9s-HODE. Conversely, upon 
stimulation with CpG in A, an increase was seen in PSG D2, PSG E2, PSG B2, and PSG A2 as 
well as TB B2, however in CpG-B, they have decreased values. Resolvin D1 is increased in 
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Discussion 
 The overarching objective of this study was to investigate the intrinsic and extrinsic 
changes associated with IFN-α production by pDCs due to various TLR agonists at the 
metabolomic and lipidomic levels. There were many strengths and weaknesses associated with 
this preliminary study. The existence of a mixed culture with other DC subsets having 
overlapping properties to pDCs made this a demanding project. Within a mixed culture, our cells 
of interest were allowed to interact with each other and with other cells in vitro. While this is 
beneficial in some respects because it mimics an in vivo environment, it is just as detrimental 
because the effects seen may be associated with cDCs and not pDCs. Further, while we were 
able to generate data from our experimentation, it is important to note that while we had enough 
cells in culture to stimulate IFN-α production, we had the minimum cell number requirement for 
the core facility to analyze phospholipid fatty acids, possibly attributing to the variability of our 
data. With a novel project, this makes data highly variable. Further, an adjustment to the 
stimulation protocol needs to be made as it seems there was possible inflammatory mediation 
occurring in CpG-B.  Lastly, as previously stated, current research has focused on the effects that 
dietary DHA has on immune cells, such as T lymphocytes, B lymphocytes, and monocytes. 
Because of this, the focus of this study was to begin exploring the effects that TLR stimulation of 
IFN-α production of pDCs had on phospholipid fatty acids and eicosanoid production, making 
the data obtained from this study extremely novel and innovative. Because our laboratory was 
the first to explore this, we had no other results to compare our data to; therefore, data were 
analyzed to the best of our abilities.  
 In this study, we created an inflammatory environment by stimulating bone marrow 
derived dendritic cells through TLRs specific to pDCs. Cells were stimulated with TLR3 agonist 
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poly(I:C) to induce an antiviral inflammatory response and with the TLR9 agonist unmethylated 
CpG ODN1585 to induce an antibacterial inflammatory. A murine IFN-α ELISA was performed 
to confirm and quantify the production of IFN-α.  From the ELISA, it was determined that IFN-α 
production occurred due to TLR9 stimulation with ssDNA agonist unmethylated ODN1585 
CpG, backing numerous studies (Björck et al, 2011; Krung, 2001). Conversely, IFN-α 
production was not quantifiable or detectable through TLR3 stimulation with dsRNA agonist 
poly(I:C) or through TLR7/8 ssRNA agonist R848 despite research showing R848 is a potent 
stimulator of IFN-α production in murine pDCs (Gibson et al, 2002). Further experimentation is 
needed to allow for proper dosing of R848 to stimulate IFN-α production in murine pDCs.  
Pellets of our stimulated, mixed cell cultures were sent to Michigan Regional 
Comprehensive Metabolomics Core Facility for phospholipid fatty acid analysis. While we had 
sufficient cells in culture to induce IFN-α production, the number of cells sent to the core facility 
was the minimum they were able to test, making accurate phospholipid fatty acid measures 
difficult. However, data showed an increase in total phospholipid fatty acids across both 
stimulations with ODN 1585 CpG and poly(I:C) as compared to the no target sample. Increases 
in both saturated and unsaturated fatty acids were seen; however, the amount of unsaturated fatty 
acids that increased or decreased in number across stimulations was much larger. This is 
important to note because changes in fatty acid content affects membrane fluidity. Through 
increasing the amount of saturated phospholipid fatty acids, the membrane becomes stiff and less 
viscous, resulting in decreased membrane fluidity. Conversely, by increasing the number of 
unsaturated phospholipid fatty acids, the double bonded carbon atoms of the bent fatty acid 
chains create difficulty for the phospholipids to pack tightly together thereby making the 
membrane more fluid. Altering the membrane fluidity alters membrane-regulated functions such 
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as phagocytosis, specific surface protein-protein interactions, and cellular signaling, further 
changing the dynamics and responsiveness of the cell to different types of stimuli (Boheim et al, 
1980). It is also important to note the change in total phospholipid fatty acid concentration seen 
in CpG-A associated with IFN-α production. From these data, we can conclude that phospholipid 
fatty acids are increasing to begin producing inflammatory resolving mediators, as seen by the 
increase in total eicosanoid concentrations seen in CpG-B.  
Phospholipid fatty acid analysis shows a decrease in phospholipid fatty acid 
concentrations of ω-6 PUFA, arachidonic acid during poly(I:C) stimulations and CpG-A 
stimulations. Our results also present a decrease in arachidonic acid precursors in CpG-A 
stimulation. Dihomo-γ-linolenic acid and γ -linoleic acid are precursors for the production of 
arachidonic acid from essential fatty acid linoleic acid. Dietary linoleic acid is desaturated by Δ6 
desatuase to γ-linoleic acid. γ-linoleic acid is elongated to form dihomo- γ-linolenic acid which is 
further desaturated through Δ5 desaturase to produce arachidonic acid. To sustain production of 
these eicosanoids, arachidonic acid needs to be replaced. Depleting levels of arachidonic acid are 
replenished through the desaturation and elongation of these precursors (γ-linoleic acid and 
dihomo- γ-linolenic acid) to produce arachidonic acid. Our data suggests that γ-linoleic acid is 
being delpleated and elongated to dihomo- γ-linolenic acid and further desaturated to arachidonic 
acid to continue producing pro-inflammatory arachidonic acid derived eicosanoids in response to 
the inflammatory enviroment created by stimulaiton with poly(I:C) and CpG-A. Eicosanoid 
analysis further validates these phospholipid fatty acid changes. Data show an increase in 
arachidonic acid cyclooxygenase derived metabolites, such as prostaglandin D2, prostaglandin 
E2, prostaglandid A2, prostaglandin B2, and thromboxane B2. Conversely, data show decreases in 
arachidonic acid lipoxygenase derived metabolites such as 15-HETE, 12-HETE, 12oxoETE, and 
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5-HETE with CpG-A stimulation. An increase in oxidized linoleic acid metabolites 13s-HODE 
and 9s-HODE was noted across stimultaions with poly(I:C) and CpG-A indicitave of their role in 
inflammation; however, both decreased in CpG-B. To further all of this, analysis of the ω-6: ω-3 
ratio indicated that upon stimulation with poly(I:C), the ratio shifted towards ω-3 PUFAs (Table 
4). Conversely, with CpG stimulation of IFN-α production, the ω-6: ω-3 ratio shifted towards 
W-6 PUFAs, showing that when IFN-α is induced, there is an increase of ω-6 PUFAs to sustain 
pro-inflammatory cytokine production along with the increase in pro-inflammatory 
cyclooxygenase eicosanoid mediator production.   
A decrease in palmitoleic acid (16:1) was noted with CpG-A alone, indicative of being a 
possible change due to IFN-α production. Palmitoleic acid is a monosaturated fatty acid with 
anti-inflammatory properties. Palmitoleic acid, when present, reduces inflammatory cytokines 
such as NFκB and inflammatory genes of the inflammasome complex independent of PPARα, 
PPARγ, and AMPK (Souza et al, 2017). Our studies showed a decrease in palmitoleic acid with 
CpG-A, further increasing the inflammatory environment through potential dysregulated NFκB 
expression. We can conclude that dysregulated NFκB expression may occur due to IFN-α 
activation of an alternative NFκB pathway furthering the inflammatory environment (Yang et al, 
2005). However, further experimentation would be needed to confirm these results. 
On the contrary, the results from CpG-B stimulation differed vastly from CpG-A. Our 
findings from the stimulation show a decrease in all measured arachidonic acid cyclooxygenase 
derived metabolites, such as prostaglandins and thromboxane B2. This is confirmed through 
phospholipid fatty acid analysis showing an increase in arachidonic acid as well as arachidonic 
acid precursor dihomo-γ-linolenic acid. Because arachidonic acid utilization has decreased, we 
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see an increase in these. Also, the arachidonic acid lipoxygenase derived mediators remained 
decreased, indicating possible inflammatory mediation occuring.  
As a compensatory mechanism to inflammatory resolution, anti-inflammatory lipid 
mediators such as E-and D-series resolvins, protectins, and maresins are derived from ω-3 
polyunsaturated fatty acids EPA/DHA. Lipoxins are pro-resolving mediators derived from the 
oxidation of arachidonic acid or EPA (Serhan et al, 1984). α-linolenic acid is an essential dietary 
n-3 polyunsaturated fatty acid and can be enzymatically desaturated by Δ6 desaturase to 
stearidonic acid (18:4n-3), elongated via elongase to eicosatetraenoic acid (20:4n-3), and further 
desaturated via Δ5 desaturase to form EPA. Analysis of phospholipid fatty acids shows a 
decrease in α-linolenic acid and EPA and an increase in DHA and DHA-derived resolvin D1. 
This suggests that that α-linolenic acid was being desaturated and elongated to EPA to be 
oxidized to pro-resolving lipoxins via 15-lipoxygenase to aid in the mediation of the 
inflammatory microenvironment. Further, DPA (22:5) and DHA (22:6) are produced in lower 
amounts in CpG-A. However, in CpG-B, both are produced in much larger amounts in CpG-B, 
with DPA being slightly more than DHA. Because DPA is able to be desaturated through Δ4 
desaturase to produce DHA (Park et al, 2015), it is possible that DPA is being desaturated to 
produce the DHA needed for the resolution of inflammation via D-series resolvins, protectins, 
and maresins. While we are limited to the results of those detectible mediators from the 
metabolomics analysis (resolvin D1, resolvin D2, and resolvin E1), we are not able to account 
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Due to the protective nature of DHA, it has been a potential treatment or complementary 
approach in treatment of inflammatory conditions such as atherosclerosis (Van Noolen et al, 
2014), colitis (Arita et al, 2005), rheumatoid arthritis (Lima-Garcia et al, 2011), and lupus (Bates 
et al, 2017). EPA can be retroconverted to DHA, although in minimal amounts; therefore, dietary 
supplementation is necessary. When taken in through dietary means or supplementation, DHA is 
able to incorporate into the phospholipid bilayer of cells and does so by competitively displacing 
arachidonic acid, lowering the ω-6 index. This further reduces the substrate needed for pro-
inflammatory eicosanoid production.  Research has shown that diets with excess ω-6 fatty acid 
consumption increases the risk of certain diseases, such as cardiovascular disease through 
atherosclerotic plaques. Typical Western diets have high dietary ω-6 fatty acid ratios as high as 
20:1, while an optimal dietary ω-6 to ω-3 fatty acid ratio is 4:1 or lower (Pestka et al., 2014). 
Further studies have indicated that supplemental DHA is able to suppress and reverse the 
progression of inflammation, inflammatory cell involvement, inflammasome activation, and 
regulating clearance of necrotic cells in inflammatory and autoimmune diseases (Xiong et al, 
2005). 
The observations from this study provide a platform for further exploration. Going on 
with future experimentation will include positive or negative selection of pDCs to obtain a pure 
culture. Not only will this concentrate our pDCs, it will also allow us to differentiate between 
those eicosanoid and phospholipid fatty acid changes seen in this experiment that were 
associated with cDCs responding to IFN-α production. Also, because dendritic cells are a 
cellular bridge between innate and adaptive immunity, they are able to secrete many chemokines 
to attract varying immune cell types at specific times in the immune response. Some secreted 
cytokines include IL-6, IL-10, IL-12, and IL-23. Assaying for any of these cytokines will give us 
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insight as to how dendritic cells are able to polarize naïve T cells into Th1, Th2, or Treg cells 
during IFN-α stimulation. From there, we will be able to look for differences between 
eicosanoids and fatty acids due to cytokine production and IFN-α production. Going further, the 
TLR stimulation time course should be adjusted accordingly to sustain the inflammatory 
response for further analysis and to avoid pro-resolving mediation of the inflammatory response. 
This will allow us a clearer picture of the eicosanoid and phospholipid fatty acid changes that are 
being seen due to IFN-α production. From this we will also be able to determine whether IFN-α 
production is responsible for resolvin production or if timing due to pro-resolving mediator 
production is responsible. This will also give us insight into whether the pro-resolving lipid 
mediators are blunting the IFN-α response. Finally, IFN-α producing pDCs will be treated with 
DHA in vitro to determine DHA incorporation into phospholipid fatty acids, eicosanoids and 
mediators changes due to DHA treatment, modulation of IFN-α production, and effects on 
cytokine production.  
From our studies, we were able to confirm that INF-α production in murine bone 
marrow-derived dendritic cells occurs through TLR9 stimulation with ODN 1585 CpG. We were 
able to determine that due to IFN-α production, a decrease in arachidonic acid and arachidonic 
acid precursors occurred along with an upregulation of arachidonic acid metabolites of the 
cyclooxygenase pathway, suggesting that arachidonic acid is being used to sustain pro-
inflammatory eicosanoid production. Furthering this, we saw greater than a two-fold increase in 
ω-6: ω-3 ratio towards ω-6 PUFAs in TLR9 stimulation with CpG, showing that a shift in the ω-
6: ω-3 ratio is needed to sustain the pro-inflammatory environment. Although our 
experimentation was novel and innovative, it was also full of many challenges. From our 
experimentation, we were able to gather sufficient preliminary data to warrant further 
40 | P a g e  
 


















41 | P a g e  
 
Appendices 
Appendix I: Explanation of Acronyms 
ADs (Autoimmune Diseases) 
pDCs (Plasmacytoid dendritic cells) 
TLR (Toll-like receptor) 
PAMP (pathogen-associated molecular pattern) 
PRR (pattern precognition receptor) 
IFN-α (interferon alpha) 
IFN-β (interferon beta) 
MyD88- (myeloid differentiation primary response protein 88) 
RNA- ribonucleic acid 
ssDNA (single-stranded deoxyribonucleic acid) 
IRAK (interleukin-1 receptor (IL-1R) associated kinase 1) 
IFNAR1 (Interferon alpha receptor 1) 
JAK/STAT (Janus kinase/ signal transducers and activators of transcription) 
ISGs (interferon stimulated genes) 
NSAID (non-steroidal anti-inflammatory) 
PUFAs (polyunsaturated fatty acids) 
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MHC II (major-histocompatability complex II) 
DHA (docosahexaenoic acid) 
EPA (eicosapentaenoic acid) 
Poly I:C (polyinosinic-polycytidylic acid) 
ELISA (enzyme-linked immunosorbent assay) 
FLT3-L (FMS-like tyrosine kinase 3) 
TMB- 3,3’,5,5’-tetramethylbenzidine  
HRP- horseradish peroxidase 
ACK- ammonium-chloride-potassium 
RPMI media- Roswell Park Memorial Institute 
FACS- fluorescence activated cell sorting  
LCMS- liquid chromatography-mass spectrometry  
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Appendix II: Table 5- Murine IFN-α ELISA Concentrations 
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